Handheld ultrasound pioneer SonoSite announced Jan. 15 that it had received clearance from the Japanese Ministry of Health, Labor, and Welfare to market and distribute its SonoSite 180PLUS and the SonoHeart PLUS products. They are enhanced versions of
Handheld ultrasound pioneer SonoSite announced Jan. 15 that it had received clearance from the Japanese Ministry of Health, Labor, and Welfare to market and distribute its SonoSite 180PLUS and the SonoHeart PLUS products. They are enhanced versions of other SonoSite products already being sold in the Japanese marketplace by SonoSite in collaboration with Olympus Optical. A week earlier, SonoSite released details about the start of a direct sales operation in Germany. The newly formed SonoSite GmbH officially opened Jan. 2, following introduction of the company's handheld products at the November 2001 Medica meeting in Dusseldorf. Cornel Schoelgens has been recruited to manage German operations as well as distribution in Austria and Switzerland. Schoelgens is a 20-year veteran of the diagnostic imaging industry, having held positions with GE Medical Systems and Acuson. SonoSite has direct sales operations in the U.S., the U.K., France, and Germany. It will soon begin direct sales in Spain.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.